We are live on
!
Find out more
PM
Prosight Management Portfolio holdings
AUM
$580M
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+4.88%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$198M
AUM Growth
-$30.2M
(-13%)
Cap. Flow
-$17.6M
Cap. Flow
% of AUM
-8.86%
Top 10 Holdings %
Top 10 Hldgs %
61.84%
Holding
46
New
8
Increased
13
Reduced
18
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kura Oncology
KURA
|
+$11.5M |
| 2 |
Q32 Bio
QTTB
|
+$8.06M |
| 3 |
uniQure
QURE
|
+$7.65M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$5.94M |
| 5 |
SBBP
Strongbridge Biopharma plc.
SBBP
|
+$5.92M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cigna
CI
|
+$16.7M |
| 2 |
WCG
Wellcare Health Plans, Inc.
WCG
|
+$9.43M |
| 3 |
HNGR
Hanger Inc.
HNGR
|
+$8.55M |
| 4 |
Iovance Biotherapeutics
IOVA
|
+$7.79M |
| 5 |
NVRO
NEVRO CORP.
NVRO
|
+$7.33M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.24% |
| 2 | Technology | 0.92% |
| 3 | Miscellaneous | 0.84% |
| 4 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Zimmer Biomet
ZBH
$19.2B
| $19.4M | 9.77% |
169,558
+42,353
| +33% | +$4.96M |
|
|
2
Bristol-Myers Squibb
BMY
$136B
| $18.6M | 9.39% |
410,490
+127,490
| +45% | +$5.94M |
|
|
3
Kura Oncology
KURA
$1.13B
| $17.1M | 8.62% |
867,810
+694,916
| +402% | +$11.5M |
|
|
RETA
4
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $11.8M | 5.94% |
124,965
-50,735
| -29% | -$4.38M |
|
|
5
Iovance Biotherapeutics
IOVA
$3.63B
| $9.81M | 4.95% |
400,000
-517,080
| -56% | -$7.79M |
|
|
ARNA
6
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $9.63M | 4.86% |
164,300
-88,200
| -35% | -$4.56M |
|
|
HNGR
7
DELISTED
Hanger Inc.
HNGR
| $9.42M | 4.75% |
491,685
-441,863
| -47% | -$8.55M |
|
|
8
uniQure
QURE
$3.38B
| $9.38M | 4.73% |
+120,000
| New | +$7.65M |
|
9
UroGen Pharma
URGN
$2.13B
| $9.38M | 4.73% |
260,928
+103,066
| +65% | +$3.8M |
|
|
ALBO
10
DELISTED
Albireo Pharma Inc
ALBO
| $8.17M | 4.12% |
253,327
-16,509
| -6% | -$552K |
|
|
SBBP
11
DELISTED
Strongbridge Biopharma plc.
SBBP
| $7.97M | 4.02% |
2,546,997
+1,613,121
| +173% | +$5.92M |
|
|
12
Q32 Bio
QTTB
$447M
| $7.22M | 3.64% |
+20,503
| New | +$8.06M |
|
|
CLVS
13
DELISTED
Clovis Oncology, Inc.
CLVS
| $6.69M | 3.37% |
450,000
+200,611
| +80% | +$3.62M |
|
14
Centene
CNC
$32B
| $6.63M | 3.34% |
126,500
+48,100
| +61% | +$2.6M |
|
|
15
Cigna
CI
$73.7B
| $4.92M | 2.48% |
31,227
-106,773
| -77% | -$16.7M |
|
16
BioMarin Pharmaceuticals
BMRN
$12.5B
| $4.38M | 2.21% |
51,200
-6,184
| -11% | -$529K |
|
17
Aldeyra Therapeutics
ALDX
$89.9M
| $4.19M | 2.11% |
697,921
+114,621
| +20% | +$863K |
|
18
Gyre Therapeutics
GYRE
$699M
| $4.03M | 2.03% |
72,946
+8,386
| +13% | +$524K |
|
19
Indaptus Therapeutics
INDP
$152M
| $3.54M | 1.79% |
364
+122
| +50% | +$1.54M |
|
20
AC Immune
ACIU
$263M
| $3.13M | 1.58% |
563,900
-146,641
| -21% | -$747K |
|
21
Assembly Biosciences
ASMB
$694M
| $2.7M | 1.36% |
16,667
-9,534
| -36% | -$1.81M |
|
|
TLGT
22
DELISTED
Teligent, Inc
TLGT
| $1.87M | 0.94% |
296,772
-7,385
| -2% | -$60.2K |
|
|
WCG
23
DELISTED
Wellcare Health Plans, Inc.
WCG
| $1.85M | 0.93% |
6,500
-34,200
| -84% | -$9.43M |
|
|
EFOR
24
Everforth Inc
EFOR
$1.31B
| $1.82M | 0.92% |
30,000
-79,116
| -73% | -$4.75M |
|
|
EXAS
25
PUT
DELISTED
Exact Sciences
EXAS
| $1.66M | 0.84% |
14,100
-40,400
| -74% | -$4.07M |
|
Similar funds
SC
CCWM
CMA
RIS
MFS
GFI
PWM
CA
Prosight Management's Q2 2019 Portfolio in Review
As of Q2 2019, Prosight Management held 46 positions worth $198M, down 13% from $229M the previous quarter. Its ten largest holdings account for 62% of the portfolio.
Prosight Management withdrew a net $17.6M in Q2 2019, closing 7 positions and reducing 18 holdings. Its most notable exit was WageWorks, Inc., an estimated $4.38M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 90% a quarter earlier, followed by Technology and Miscellaneous.
Against the trend, Prosight Management opened a new position in Q32 Bio worth $7.22M.
- Prosight Management's largest Q2 2019 buy was Q32 Bio: 20,503 shares worth $7.22M.
- Prosight Management added most to Kura Oncology in Q2 2019, an estimated $11.5M increase.
- Prosight Management's biggest Q2 2019 reduction was Cigna, cutting an estimated $16.7M.
- Prosight Management fully exited WageWorks, Inc. in Q2 2019, selling an estimated $4.38M.
- Prosight Management's ten largest holdings make up 62% of its $198M portfolio in Q2 2019.
- Prosight Management opened 8 new positions and closed 7 in Q2 2019.
- Prosight Management's portfolio value fell 13% quarter-over-quarter to $198M.
Based on Prosight Management's 13F filing for Q2 2019, filed 14 Aug 2019.